Multimodality treatment for locally advanced renal cancer

Abstract

Multiple antitumor therapy in patients with locally advanced renal cancer leads to a 2.3-fold reduction in the incidence of recurrences during 2 years, as compared to a control group and to a 1.7-fold increase in 5-year survival rates.

Magnetotherapy used as part of multimodality treatment for locally advanced renal cancer can lower the incidence of postoperative complications by 1.9 times and the frequency of side effects during teleradiotherapy by 1.4 times.

Recombinant tumor necrosis factor- α activates cellular immunity, as reflected in the immune status as increases in the absolute count of T lymphocytes and their active forms by 44.9 and 33.71%, respectively.

In patients with Bcl-2+/Ki-67⁺ (24%), had the lowest relapse-free survival rates (median 16 months; 95% CI 8—24 months) whereas those (58%) with Bcl-2-/p53⁺ had the highest ones (median not being achieved). The phenotype Bcl-2⁺/Ki-67⁺ characterizes a more aggressive course of renal cancer and has a poor prognosis.